2. Search Result
Search Result
Results for "

p38+MAPK+inhibitor

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10256
    Adezmapimod
    Maximum Cited Publications
    601 Publications Verification

    SB 203580; RWJ 64809

    		 Organoid p38 MAPK Autophagy Mitophagy HSP Inflammation/Immunology Cancer
    Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .
    Adezmapimod
  • HY-10320
    Doramapimod
    50+ Cited Publications

    BIRB 796

    		 p38 MAPK Raf Autophagy Inflammation/Immunology Cancer
    Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM .
    Doramapimod
  • HY-10402
    Losmapimod
    10+ Cited Publications

    GSK-AHAB; GW856553X; SB856553

    		 p38 MAPK Autophagy Inflammation/Immunology Cancer
    Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively .
    Losmapimod
  • HY-10256A
    Adezmapimod hydrochloride
    Maximum Cited Publications
    601 Publications Verification

    SB 203580 hydrochloride; RWJ 64809 hydrochloride

    		 Organoid p38 MAPK Autophagy Mitophagy Inflammation/Immunology Cancer
    Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an autophagy and mitophagy activator .
    Adezmapimod hydrochloride
  • HY-10456
    TAK-715
    10+ Cited Publications

    		 p38 MAPK Casein Kinase Wnt Inflammation/Immunology
    TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model .
    TAK-715
  • HY-19900
    ITX5061
    3 Publications Verification

    		 p38 MAPK Scavenger Receptor Class B type I (SR-BI） Inflammation/Immunology
    ITX5061 is an orally active type II non-competitive p38 MAPK inhibitor. ITX5061 increases HDL-C levels by inhibiting SR-BI activity. ITX5061 also moderately elevates ApoA-I levels. ITX5061 reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 can be used in the research of atherosclerosis .
    ITX5061
  • HY-100115
    TA-02
    2 Publications Verification

    		 p38 MAPK Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295) .
    TA-02
  • HY-11068
    SB 239063
    30+ Cited Publications

    		 p38 MAPK Autophagy Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SB 239063 is a potent, selective and orally active p38 MAPK inhibitor, exhibits an IC50 of 44 nM for recombinant purified human p38α, with equipotent inhibitory activity against p38α and p38β. SB 239063 has no effect on p38γ or p38δ. With anti-asthma activity and also be used to enhance memory which is impaired due to aging or medical conditions, such as, AD. SB 239063 can penetrate the blood brain barrier (BBB) .
    SB 239063
  • HY-10404
    Dilmapimod
    1 Publications Verification

    SB-681323; GW 681323

    		 p38 MAPK Autophagy Inflammation/Immunology Cancer
    Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
    Dilmapimod
  • HY-100114
    TA-01

    		Casein Kinase p38 MAPK Autophagy Cardiovascular Disease
    TA-01 is a potent CK1 and p38 MAPK inhibitor, with IC50s of 6.4 nM, 6.8 nM, 6.7 nM for CK1ε, CK1δ and p38 MAPK, respectively. TA-01 acts as a cardiogenic inhibitor.
    TA-01
  • HY-12511
    SKF-86002
    3 Publications Verification

    		 p38 MAPK Inflammation/Immunology
    SKF-86002 is an orally active p38 MAPK inhibitor, with anti-inflammatory, anti-arthritic and analgesic activities. SKF-86002 inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production (IC50 = 1 μM). SKF-86002 inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid .
    SKF-86002
  • HY-10405
    Pamapimod
    1 Publications Verification

    Ro4402257; R1503

    		 p38 MAPK Autophagy Inflammation/Immunology
    Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .
    Pamapimod
  • HY-B2162D
    Chondroitin sulfate (from chicken)

    Chondroitin polysulfate (from chicken)

    		 ERK p38 MAPK Interleukin Related TNF Receptor Prostaglandin Receptor MMP Endogenous Metabolite Inflammation/Immunology
    Chondroitin sulfate (from chicken) (Chondroitin polysulfate (from chicken)) is an orally active, sulfated linear polysaccharide extracted from chickens, which belongs to glycosaminoglycans. Chondroitin sulfate (from chicken) reduces the phosphorylation levels of ERK1/2 and p38MAPK, inhibits the expression of inflammatory cytokines and MMP, and downregulates the levels of IL-1β, IL-6, TNF-α and PGE2. Chondroitin sulfate (from chicken) improves motor function, protects cartilage tissue, reverses chondrocyte aggregation, and regulates the structure of intestinal flora. Chondroitin sulfate (from chicken) can be used in research related to osteoarthritis .
    Chondroitin sulfate (from chicken)
  • HY-112389
    p38 MAP Kinase Inhibitor III
    2 Publications Verification

    		 p38 MAPK Inflammation/Immunology
    p38 MAP Kinase Inhibitor III (compound 7h) is a p38 MAPK inhibitor with an 50 of 0.9 μM. p38 MAP Kinase Inhibitor III also inhibits IL-1β and TNF-α release with 50 values of 0.37 μM and 0.044 μM, respectively .
    p38 MAP Kinase Inhibitor III
  • HY-135674
    SR-318
    1 Publications Verification

    		 p38 MAPK TNF Receptor Inflammation/Immunology Cancer
    SR-318, a chemical probe, is a potent and highly selective p38 MAPK inhibitor with IC50s of 5 nM, 32 nM and 6.11 μM for p38α, p38β and p38α/β, respectively. SR-318 potently inhibits the TNF-α release in whole blood with an IC50 of 283 nM. SR-318 has anti-cancer and anti-inflammatory activity .
    SR-318
  • HY-18862
    PF-03715455

    		p38 MAPK Inflammation/Immunology
    PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease) .
    PF-03715455
  • HY-112291
    SB 220025

    		p38 MAPK Src PKC Inflammation/Immunology
    SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC50 = 60 nM). SB 220025 also inhibits p56 Lck and PKC with IC50 values of 3.5 and 2.89 µM, respectively. SB 220025 inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation .
    SB 220025
  • HY-112466
    p38 MAPK-IN-4

    		p38 MAPK Inflammation/Immunology
    p38 MAPK-IN-4 (compound 6) is a p38 MAPK inhibitor with an IC50 of 35 nM .
    p38 MAPK-IN-4
  • HY-10256R
    Adezmapimod (Standard)

    SB 203580 (Standard); RWJ 64809 (Standard)

    		 Organoid Reference Standards p38 MAPK Autophagy Mitophagy HSP Inflammation/Immunology Cancer
    Adezmapimod (Standard) is the analytical standard of Adezmapimod. This product is intended for research and analytical applications. Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .
    Adezmapimod (Standard)
  • HY-110103
    ML3403

    		p38 MAPK Inflammation/Immunology
    ML3403 is a potent p38 MAPK inhibitor with an IC50 of 0.38 μM .
    ML3403
  • HY-10256AR
    Adezmapimod hydrochloride (Standard)

    SB 203580 hydrochloride (Standard); RWJ 64809 hydrochloride (Standard)

    		 Organoid Reference Standards p38 MAPK Autophagy Mitophagy Inflammation/Immunology Cancer
    Adezmapimod (hydrochloride) (Standard) is the analytical standard of Adezmapimod (hydrochloride). This product is intended for research and analytical applications. Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an autophagy and mitophagy activator .
    Adezmapimod hydrochloride (Standard)
  • HY-108644
    SB 706504

    		p38 MAPK Inflammation/Immunology
    SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides (HY-D1056)-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD) .
    SB 706504
  • HY-18754A
    FR 167653

    FR 167653 sulfate

    		 p38 MAPK Autophagy Endocrinology
    FR 167653 (FR 167653 sulfate), an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 (FR 167653 sulfate) is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo .
    FR 167653
  • HY-10404A
    Dilmapimod tosylate

    SB-681323 tosylate; GW 681323 tosylate

    		 p38 MAPK Autophagy Inflammation/Immunology Cancer
    Dilmapimod tosylate is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
    Dilmapimod tosylate
  • HY-49073
    p38 MAP Kinase Inhibitor Ⅵ

    		p38 MAPK Cancer
    p38 MAP Kinase Inhibitor VI (compound c32) is a p38 MAPK inhibitor with an inhibition rate of 24% .
    p38 MAP Kinase Inhibitor Ⅵ
  • HY-169685
    p38 MAPK-IN-6

    		p38 MAPK Inflammation/Immunology
    p38 MAPK-IN-6 (compound c47) is a p38 MAPK inhibitor. p38 MAPK-IN-6 shows 14% inhibition at 10 μM .
    p38 MAPK-IN-6
  • HY-10404R
    Dilmapimod (Standard)

    SB-681323 (Standard); GW 681323 (Standard)

    		 Reference Standards p38 MAPK Autophagy Inflammation/Immunology Cancer
    Dilmapimod (Standard) is the analytical standard of Dilmapimod. This product is intended for research and analytical applications. Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
    Dilmapimod (Standard)
  • HY-10403A
    (aS)-PH-797804

    		p38 MAPK Inflammation/Immunology
    (aS)-PH-797804 is a selective p38 MAPK inhibitor with IC50 values for p38 α /β of 26 nM and 102 nM, respectively. (aS)-PH-797804 has anti-inflammatory activity .
    (aS)-PH-797804
  • HY-163114
    2-Stearoxyphenethyl phosphocholin

    		p38 MAPK Metabolic Disease
    2-Stearoxyphenethyl phosphocholin (compound 1a) is a p38 MAPK inhibitor with anticancer activity. 2-Stearoxyphenethyl phosphocholin may bind to the p38 MAPK lipid-binding pocket and has broad-spectrum anti-tumor and lipid-modulating activities .
    2-Stearoxyphenethyl phosphocholin
  • HY-163115
    2-Oleoxyphenethyl phosphocholin

    		p38 MAPK Cancer
    2-Oleoxyphenethyl phosphocholin (compound 1b) is a p38 MAPK inhibitor with anticancer activity. 2-Oleoxyphenethyl phosphocholin may bind to the p38 MAPK lipid-binding pocket and has broad-spectrum anti-tumor and lipid-modulating activities .
    2-Oleoxyphenethyl phosphocholin
  • HY-175431
    p38 MAPK-IN-8

    		p38 MAPK Inflammation/Immunology Cancer
    p38 MAPK-IN-8 (Compound 8) is an orally active, potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor. p38 MAPK-IN-8 is promising for research of inflammatory responses, autoimmune diseases, and cancer .
    p38 MAPK-IN-8
  • HY-10402R
    Losmapimod (Standard)

    GSK-AHAB (Standard); GW856553X (Standard); SB856553 (Standard)

    		 Reference Standards p38 MAPK Autophagy Inflammation/Immunology Cancer
    Losmapimod (Standard) is the analytical standard of Losmapimod. This product is intended for research and analytical applications. Losmapimod (GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKis of 8.1 and 7.6 for p38α and p38β, respectively .
    Losmapimod (Standard)
  • HY-108641
    SKF-86002 dihydrochloride

    		p38 MAPK Inflammation/Immunology
    SKF-86002 dihydrochloride is an orally active p38 MAPK inhibitor, with anti-inflammatory, anti-arthritic and analgesic activities. SKF-86002 dihydrochloride inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production (IC50 = 1 μM). SKF-86002 dihydrochloride inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid .
    SKF-86002 dihydrochloride
  • HY-175432
    p38 MAPK-IN-9

    		p38 MAPK Inflammation/Immunology
    p38 MAPK-IN-9 (Compound 15) is an orally active and highly selective p38α mitogen-activated protein kinase (p38 MAPK) inhibitor with an IC50 value of 9.6 nM. p38 MAPK-IN-9 is promising for research of inflammatory diseases such as rheumatoid arthritis, septic shock, and chronic obstructive pulmonary disease (COPD) .
    p38 MAPK-IN-9
  • HY-18754
    FR 167653 free base

    		p38 MAPK Autophagy Endocrinology
    FR 167653 free base, an orally active and selective p38 MAPK inhibitor, is a potent suppressor of TNF-α and IL-1β production via specific inhibition of p38 MAPK activity. FR 167653 free base is effective in treating inflammation, relieving trauma and ischemia-reperfusion injury in vivo .
    FR 167653 free base
  • HY-13478
    AS1940477

    		p38 MAPK TNF Receptor Interleukin Related Inflammation/Immunology
    AS1940477 (Compound 3f) is an orally active p38 MAPK inhibitor. AS1940477 inhibits the enzymatic activity of recombinant p38α and β isoforms. AS1940477 inhibits the production of pro-inflammatory cytokines (including TNFα, IL-1β, and IL-6) in human synovial interstitial cells and animal models of inflammation. AS1940477 can be used in research on inflammatory diseases .
    AS1940477
  • HY-12511R
    SKF-86002 (Standard)

    		p38 MAPK Inflammation/Immunology
    SKF-86002 (Standard) is the analytical standard of SKF-86002. This product is intended for research and analytical applications. SKF-86002 is an orally active p38 MAPK inhibitor, with anti-inflammatory, anti-arthritic and analgesic activities. SKF-86002 inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production (IC50 = 1 μM). SKF-86002 inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid .
    SKF-86002 (Standard)
  • HY-10405R
    Pamapimod (Standard)

    Ro4402257 (Standard); R1503 (Standard)

    		 Reference Standards p38 MAPK Autophagy Inflammation/Immunology
    Pamapimod (Standard) is the analytical standard of Pamapimod. This product is intended for research and analytical applications. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .
    Pamapimod (Standard)
  • HY-10405S
    Pamapimod-d4

    		Isotope-Labeled Compounds p38 MAPK Autophagy Inflammation/Immunology
    Pamapimod-d4 (Ro4402257-d4) is the deuterium labeled Pamapimod. Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC50s of 14 nM and 480 nM and Kis of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment .
    Pamapimod-d4
  • HY-112291A
    SB 220025 (tri(hydrochloride))

    		p38 MAPK Src PKC Inflammation/Immunology
    SB 220025 trihydrochloride is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC50 = 60 nM). SB 220025 trihydrochloride also inhibits p56 Lck and PKC with IC50 values of 3.5 and 2.89 μM, respectively. SB 220025 trihydrochloride inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 trihydrochloride effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation .
    SB 220025 (tri(hydrochloride))
  • HY-10320R
    Doramapimod (Standard)

    BIRB 796 (Standard)

    		 Reference Standards p38 MAPK Raf Autophagy Inflammation/Immunology Cancer
    Doramapimod (Standard) is the analytical standard of Doramapimod. This product is intended for research and analytical applications. Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM .
    Doramapimod (Standard)
  • HY-110103R
    ML3403 (Standard)

    		p38 MAPK Inflammation/Immunology
    ML3403 (Standard) is the analytical standard of ML3403. This product is intended for research and analytical applications. ML3403 is a potent p38 MAPK inhibitor with an IC50 of 0.38 μM .
    ML3403 (Standard)
  • HY-123670
    RPR-200765A methanesulfonate

    		p38 MAPK TNF Receptor Inflammation/Immunology
    RPR-200765A methanesulfonate is an orally active p38 MAPK inhibitor with an IC50 of 0.050 μM. RPR-200765A methanesulfonate shows weak activity against Lck, and exhibits no significant activity against ERK, ZAP70 or SYK. It inhibits the production of TNFα and can be used in the research of inflammatory diseases .
    RPR-200765A methanesulfonate
  • HY-P11650
    HE4-1 leech peptide

    		p38 MAPK JNK Cardiovascular Disease
    HE4-1 leech peptide is a p38 MAPK inhibitor with an additional c-Jun N-terminal kinase (JNK) inhibitory role. HE4-1 leech peptide suppresses macrophage migration, and does not significantly affect macrophage immunological activities including phagocytic ability, lysozyme activity, and expression levels of most inflammatory factors. HE4-1 leech peptide can be used for the research of atherosclerosis .
    HE4-1 leech peptide
  • HY-W714214
    Ethalfluralin

    		Herbicide Microtubule/Tubulin PI3K Akt Apoptosis Autophagy Reactive Oxygen Species (ROS) NF-κB p38 MAPK Infection
    Ethalfluralin is a dinitroaniline herbicide and microtubule inhibitor. Ethalfluralin blocks nuclear division and cytokinesis of parasites by inhibiting intranuclear spindle formation. Ethalfluralin activates the phosphorylation levels of NF-κB and P38 MAPK, inhibits the PI3K/AKT signaling pathway, impairs mitochondrial function, and induces apoptosis, endoplasmic reticulum stress, autophagy, and ROS production. Ethalfluralin is applicable to research related to toxoplasmosis .
    Ethalfluralin
  • HY-100115R
    TA-02 (Standard)

    		p38 MAPK Reference Standards Autophagy Cardiovascular Disease Inflammation/Immunology Cancer
    TA-02 (Standard) is the analytical standard of TA-02 (HY-100115). This product is intended for research and analytical applications. TA-02, an analog of SB 203580 (HY-10256), is a p38 MAPK inhibitor with an IC50 of 20 nM. TA-02 especially inhibits TGFBR-2. TA-02 exhibits similar cardiogenic properties as SB 203580 and SB 202190 (HY-10295) .
    TA-02 (Standard)
  • HY-122068
    ITX5061 free base

    		p38 MAPK Scavenger Receptor Class B type I (SR-BI） Inflammation/Immunology
    ITX5061 free base is an orally active type II non-competitive p38 MAPK inhibitor. ITX5061 free base increases HDL-C levels by inhibiting SR-BI activity. ITX5061 free base also moderately elevates ApoA-I levels. ITX5061 free base reduces early atherosclerotic lesions in the aortic arch of mice fed an atherogenic diet. ITX5061 free base can be used in the research of atherosclerosis .
    ITX5061 free base
  • HY-182818
    SH494

    		p38 MAPK Keap1-Nrf2 Reactive Oxygen Species (ROS) Metabolic Disease
    SH494 is a p38 MAPK inhibitor and Nrf2 pathway activator. SH494 inhibits RANKL-induced phosphorylation of p38 and disrupts the MAPK cascade associated with osteoclastogenesis. SH494 activates the Nrf2 pathway, upregulates downstream target genes and induces the expression of cytoprotective enzymes. SH494 reduces intracellular ROS accumulation and restores mitochondrial membrane potential (ΔΨm) to normal. SH494 decreases osteoclast activity and alleviates osteoporosis symptoms in ovariectomized mice. SH494 can be used for research on osteoporosis .
    SH494
  • HY-10456R
    TAK-715 (Standard)

    		Reference Standards p38 MAPK Casein Kinase Wnt Inflammation/Immunology
    TAK-715 (Standard) is the analytical standard of TAK-715 (HY-10456). This product is intended for research and analytical applications. TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model .
    TAK-715 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: